{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:31:57Z","timestamp":1791297117809,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2014,3,26]],"date-time":"2014-03-26T00:00:00Z","timestamp":1395792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Octreotide long\u2010acting repeatable (LAR) is indicated for the treatment of carcinoid syndrome and diarrhea related to VIPoma, and may delay tumor growth in patients with neuroendocrine tumors (NETs). To the authors' knowledge, the pattern of octreotide LAR use in clinical practice and its impact on survival outcomes has not been well documented.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Using the Surveillance, Epidemiology, and End Results (SEER)\u2010Medicare database, the authors identified patients with NET aged\u2009\u2265\u200965 years who were diagnosed between July 1999 and December 2007. Patients with US Food and Drug Administration\u2010approved indications for octreotide LAR were identified from Medicare claims. Multivariate logistic regression was performed to ascertain factors associated with octreotide LAR use, whereas the Cox proportional hazards model was used to evaluate the impact of octreotide LAR on survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Among those with Food and Drug Administration\u2010approved indications, 245 of 4848 patients with distant\u2010stage disease (51%) and 81 of 807 patients with local\/regional disease (10%) initiated treatment with octreotide LAR within 6 months of diagnosis. Multivariate logistic regression indicated that among those with distant\u2010stage disease, older age (\u2265 80 years vs 65\u201069 years) (odds ratio [OR], 0.43; 95% confidence interval [95% CI], 0.23\u20100.81), female sex (OR, 0.62; 95% CI, 0.40\u20100.97), and living in the South (vs Northeast) (OR, 0.36; 95% CI, 0.18\u20100.72) were associated with a lower likelihood of using octreotide LAR. The multivariate proportional hazards model showed that octreotide LAR provided a significant 5\u2010year survival benefit for patients with distant\u2010stage disease (hazards ratio, 0.61; <jats:italic>P<\/jats:italic>\u2009\u2264\u2009.001), whereas this survival benefit was not shown for the patients with local\/regional stage (hazards ratio, 0.88; <jats:italic>P<\/jats:italic>\u2009=\u2009.563).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The results of this retrospective study suggest a possible survival benefit for the use of octreotide LAR in elderly patients with distant\u2010stage NET with carcinoid syndrome. The results of the current study also suggest that octreotide LAR is underused in this population despite recommended guidelines. <jats:bold><jats:italic>Cancer<\/jats:italic> 2014;120:2039\u20132049.<\/jats:bold> \u00a9 <jats:italic>2014 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.28653","type":"journal-article","created":{"date-parts":[[2014,3,26]],"date-time":"2014-03-26T11:29:11Z","timestamp":1395833351000},"page":"2039-2049","source":"Crossref","is-referenced-by-count":20,"title":["Octreotide long\u2010acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: A population\u2010based analysis"],"prefix":"10.1002","volume":"120","author":[{"given":"Chan","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Health Services Research The University of Texas MD Anderson Cancer Center Houston Texas"},{"name":"Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya\u2010Chen Tina","family":"Shih","sequence":"additional","affiliation":[{"name":"Section of Hospital Medicine, Department of Medicine University of Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Health Services Research The University of Texas MD Anderson Cancer Center Houston Texas"},{"name":"Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,3,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn275"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1200609"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003825"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4377"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.600"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0050"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq192"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000111034"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebb2a5"},{"key":"e_1_2_7_13_1","unstructured":"National Cancer Institute. Surveillance Epidemiology and End Results Program.seer.cancer.gov\/. Accessed March 3 2014."},{"issue":"8","key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"IV","DOI":"10.1097\/00005650-200208001-00002","article-title":"Overview of the SEER\u2010Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren JL","year":"2002","journal-title":"Med Care"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(93)90103-8"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00256-0"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/109662102320880525"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.whi.2007.03.002"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V115958"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.142"},{"key":"e_1_2_7_23_1","unstructured":"IPSEN Innovation for Patient Care. Detailed Results of the Phase III CLARINET Study at the European Cancer Congress 2013 on 28 September 2013.ipsen.com\/wp\u2010content\/uploads\/2013\/09\/PR\u2010Dates\u2010Late\u2010breaking\u2010news\u2010and\u2010Press\u2010conference\u2010Clarinet\u2010EN.pdf. Accessed March 3 2014."},{"key":"e_1_2_7_24_1","unstructured":"Surveillance Epidemiology and End Results (SEER) Program. Research Data (1973\u20102010). Bethesda MD: National Cancer Institute Division of Cancer Control and Population Sciences Surveillance Research Program Surveillance Systems Branch; 2013 based on the November 2012 submission."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28653","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:35:31Z","timestamp":1760297731000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,26]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1002\/cncr.28653"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28653","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,26]]}}}